Epithelial growth factor receptor interacting agents
Epithelial growth factor receptor interacting agents
复制标题
DOI：
10.1016/s0889-8588(02)00055-2
复制
发表时间：
2002-10-01
影响因子：
2.4
通讯作者：
Albanell, J
中科院分区：
文献类型：
--
作者：
Baselga, J;Albanell, J
上皮生长因子受体（EGFR）及其配体存在于大多数人类肿瘤中，并被认为在其临床行为中发挥作用。一系列临床前研究表明，针对EGFR的单克隆抗体和受体酪氨酸激酶（TK）活性的抑制剂可以抑制表达EGFR的癌细胞的生长。由于这些原因，egfr相互作用的药物在过去十年的末期进入了临床。目前已有临床证据表明，TK抑制剂ZD1839和OSI-774对几种肿瘤类型具有抗肿瘤活性，单克隆抗体IMC-C225能够逆转临床化疗耐药。这些结果得到了临床开发中针对EGFR的新出现的化合物、单克隆抗体和TK抑制剂的补充。在不同的药物和不同的肿瘤类型中观察到的这些发现证实了EGFR作为癌症治疗的靶点。这些药物在不同适应症和肿瘤类型中正在进行的研究结果将有助于确定这些疗法在我们目前的癌症治疗中的作用。
The epithelial growth factor receptor (EGFR) and its ligands are present in the majority of human tumors and are believed to play a role in their clinical behavior. A series of preclinical studies demonstrated that monoclonal antibodies directed at the EGFR and inhibitors of the tyrosine kinase (TK) activity of the receptor can suppress the growth of EGFR-expressing cancer cells. For these reasons, EGFR-interacting agents moved to the clinic at the end of the last decade. There is now clinical evidence of antitumor activity of the TK inhibitors ZD1839 and OSI-774 against several tumor types and of the ability of the monoclonal antibody IMC-C225 to reverse clinical chemotherapy resistance. These results are complemented by an emerging number of compounds, monoclonal antibodies, and TK inhibitors directed at the EGFR that are in clinical development. These findings observed with different agents and in different tumor types validate EGFR as a target for cancer therapy. The results of ongoing studies with these agents in diverse indications and tumor types will help to establish the role of these therapies within our current cancer treatments.